November 14, 2011 – ProTron Technologies announces a new approach to early detection of aneurysms in vascular systems through the patented Stethotron Cerebral Stethoscope.

November 14, 2011 — Edwards Lifesciences Corp. announced data were presented on the quality of life impact and cost effectiveness of transcatheter aortic valve replacement (TAVR) were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The data focused on patients at high risk for traditional open-heart surgery. TCT was sponsored by the Cardiovascular Research Foundation.

November 11, 2011 – Boston Scientific reported results from the EVOLVE first human use trial demonstrating the non-inferiority of the Synergy everolimus-eluting stent system compared to the Promus Element everolimus-eluting stent system in treating de novo coronary artery lesions. The trial provided 30-day clinical and six-month angiographic primary endpoint data evaluating the safety and effectiveness of the bioabsorbable polymer-coated Synergy stent. Results were presented today during a late-breaking clinical session by professor Ian T. Meredith, M.B.B.S., Ph.D., director of MonashHeart, Monash Medical Centre, Melbourne, Australia, and principal investigator of the trial, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.

November 11, 2011 – Biosensors International Group announced two-year results from the BioFreedom first-in-human trial, which showed similar clinical outcomes between BioFreedom, a polymer-free, drug-coated stent (DCS), and Boston Scientific’s Taxus Liberté drug-eluting stent (DES). There was no evidence of stent thrombosis in either trial arm. Results were presented by Professor Eberhard Grube, University Hospital Bonn, Germany, at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

November 11, 2011 — The 30-day results from the 8,500+ patient ADAPT-DES registry were presented at the 2011 TCT conference in San Francisco. Patients with high platelet reactivity, as measured by the Accumetrics VerifyNow P2Y12 test, exhibited an approximately four times higher rate of stent thrombosis than patients without high platelet reactivity.

November 11, 2011 — Maquet Cardiovascular announced U.S. Food and Drug Administration (FDA) 510(k) clearance and CE mark for its new Cardiosave intra-aortic balloon pump (IABP). The announcement came at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco. The system is expected to be commercially available in the United States in January 2012.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now